-
Drug Original use Mechanism Target cells in AD* Letrozole Breast cancer Aromatase inhibitor Neurons (excitatory/inhibitory) Irinotecan Colorectal cancer, pancreatic cancer Topoisomerase inhibitor Glial cells (astrocytes, microglia, OPCs) * This assignment is based on computational predictions from the CMap database in the study by Li et al., where each drug's transcriptomic profile significantly reversed the disease-associated signatures in the respective cell types[8]. Table 1.
Rationale for the combination of letrozole and irinotecan.
Figures
(0)
Tables
(1)